Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 6/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 4/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | RECQL | P46063 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | APEX1 | P27695 | 2/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Normetanephrine SCHEMBL137755 | 1.00 | NFKB1 (1.00) | NFKB1BLMPMP22TSHRCYP3A4 | |
| Normetanephrine SCHEMBL29516838 | 1.00 | NFKB1 (1.00) | NFKB1BLMPMP22TSHRCYP3A4 | |
| Normetanephrine SCHEMBL1168235 | 0.98 | BLM (1.00) | NFKB1BLMPMP22TSHRCYP3A4 | |
| Normetanephrine SCHEMBL15421560 | 0.97 | NFKB1 (0.94) | NFKB1BLMPMP22TSHRCYP3A4 | |
| Normetanephrine SCHEMBL11341275 | 0.92 | NFKB1 (0.85) | NFKB1BLMPMP22TSHRCYP3A4 | |
| Normetanephrine SCHEMBL28288010 | 0.91 | NFKB1 (0.83) | NFKB1BLMPMP22TSHRCYP3A4 | |
| Metanephrine SCHEMBL2771744 | 0.90 | NFKB1 (0.81) | NFKB1BLMPMP22TSHRCYP3A4 | |
| SCHEMBL3175780 | 0.86 | NFKB1 (0.74) | NFKB1BLMPMP22TSHRCYP3A4 | |
| Normetanephrine Hydrochloride SCHEMBL7153624 | 0.86 | NFKB1 (0.76) | NFKB1BLMPMP22TSHRCYP3A4 | |
| Normetanephrine Hydrochloride SCHEMBL11573078 | 0.86 | NFKB1 (0.76) | NFKB1BLMPMP22TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4181781-B1 | BREATH-BASED THERAPEUTIC DRUG MONITORING METHOD | UNIV KINDERSPITAL BEIDER BASEL (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20250044306-A1 | Methods for Determining Opioid Responsiveness in the Treatment of Pain | EAST CAROLINA UNIVERSITY | 2025-02-06 | — | — | US | disclosed |
| US-20230277125-A1 | BREATH-BASED THERAPEUTIC DRUG MONITORING METHOD | UNIVERSITÄTS-KINDERSPITAL BEIDER BASEL (CH) | 2023-09-07 | — | — | US | disclosed |
| WO-2023028350-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20080167318-A1 | Pharmaceutically active pyrrolidine derivatives | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2008-07-10 | — | — | US | disclosed |
| US-7211601-B2 | Pharmaceutically active pyrrolidine derivatives | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-05-01 | — | — | US | disclosed |
| EP-1268419-B1 | PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2006-06-21 | — | — | EP | disclosed |
| EP-1268418-B1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2006-06-14 | — | — | EP | disclosed |
| US-7018988-B2 | Pharmaceutically active pyrrolidine derivatives as Bax inhibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-03-28 | — | — | US | disclosed |
| US-20030212012-A1 | Pharmaceutically active pyrrolidine derivatives | MERCK SERONO SA (CH) | 2003-11-13 | — | — | US | disclosed |
| WO-2001074769-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001072705-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-10-04 | — | — | WO | disclosed |
| US-6114582-A | DECYCLIZATION TO FORM A CHEMICAL INTERMEDIATE FOR PRODUCING AN ANTI-OBESITY AGENT AND ANTIDIABETIC AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-05 | — | — | US | disclosed |
| EP-0654534-B1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEM (JP) | 2000-03-01 | — | — | EP | disclosed |
| EP-0939134-A1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-01 | — | — | EP | disclosed |
| EP-0924194-A2 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| EP-0924193-A1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| US-5811293-A | CULTURE PRODUCT AS CHEMICAL INTERMEDIATE FOR ANTI-OBESITY AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| US-5629200-A | MICROORGANISM | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1997-05-13 | — | — | US | disclosed |
| EP-0654534-A2 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212012-A1 | Pharmaceutically active pyrrolidine derivatives | OXTR, CNR1, PRLHR | NFKB1 1472/4885BLM 4611/4885PMP22 1055/4885 |
| US-20080167318-A1 | Pharmaceutically active pyrrolidine derivatives | OXTR, PRLHR, NR0B1 | NFKB1 1588/4885BLM 4441/4885PMP22 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.